Spondylarthropathies

Heterogeneous group of arthritic diseases sharing clinical and radiologic features. They are associated with the HLA-B27 ANTIGEN and some with a triggering infection. Most involve the axial joints in the SPINE, particularly the SACROILIAC JOINT, but can also involve asymmetric peripheral joints. Subsets include ANKYLOSING SPONDYLITIS; REACTIVE ARTHRITIS; PSORIATIC ARTHRITIS; and others.

Also Known As:

Networked: 1314 relevant articles (79 outcomes, 169 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Rheumatoid Arthritis
2.	Ankylosing Spondylitis
3.	Crohn Disease (Crohn's Disease)
4.	Uveitis
5.	Inflammatory Bowel Diseases (Inflammatory Bowel Disease)

Experts

1.	De Keyser, F: 16 articles (08/2009 - 03/2000)
2.	Mielants, H: 16 articles (04/2005 - 03/2000)
3.	Veys, E M: 16 articles (04/2005 - 03/2000)
4.	Wendling, Daniel: 14 articles (10/2016 - 10/2003)
5.	De Keyser, Filip: 14 articles (09/2012 - 03/2002)
6.	Dougados, Maxime: 13 articles (01/2019 - 03/2002)
7.	Veys, Eric M: 13 articles (12/2005 - 03/2002)
8.	Berthelot, Jean-Marie: 12 articles (10/2016 - 03/2002)
9.	Baeten, Dominique: 12 articles (01/2016 - 03/2002)
10.	Baeten, D: 12 articles (04/2005 - 03/2000)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Spondylarthropathies:

1.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 06/01/2019 - "Anti-tumor necrosis factor drugs are highly effective in the treatment of spondyloarthropathies. " 09/01/2009 - "Anti-tumor necrosis factor TNF-alpha agents have been shown to be effective in spondyloarthropathies. " 12/01/2002 - "Efficacy of tumor necrosis factor alpha blockade for enthesitis in spondylarthropathy: comment on the article by Marzo-Ortega et al." 02/01/2015 - "To compare the impact of meeting specific classification criteria [modified New York (mNY), European Spondyloarthropathy Study Group (ESSG), and Assessment of SpondyloArthritis international Society (ASAS) criteria] on anti-tumor necrosis factor (anti-TNF) drug retention, and to determine predictive factors of better drug survival. " 12/01/2004 - "Inhibitors of tumor necrosis factor alpha have shown effectiveness in randomized trials for the treatment of spondyloarthropathies and ocular manifestations. "
2.	Infliximab (Remicade)FDA Link 03/01/2002 - "In this open study of infliximab in patients with active spondyloarthropathy, the significant improvement of all disease manifestations was maintained over a one year follow up period without major adverse events. " 01/01/2009 - "Infliximab was less effective in our patients with axial spondyloarthropathy than expected based on the results of controlled trials. " 04/01/2013 - "Infliximab is also effective in maintenance of remission in group of patients with spondyloarthropathy. " 08/01/2004 - ": Infliximab at the dose of 5 mg/kg per infusion has been shown effective for the treatment of active spondyloarthropathies. " 12/01/2001 - "Efficacy of infliximab (Remicade) in the treatment of spondyloarthropathies. "
3.	Adrenal Cortex Hormones (Corticosteroids)IBA 07/01/1996 - "Our goal was to prospectively study the therapeutic efficacy of CT-guided intraarticular corticosteroid instillation of inflamed sacroiliac joints (SIJs) in patients with spondyloarthropathies and to evaluate the role of MRI as a procedure for establishing the indication and for therapeutic follow-up. " 01/01/1999 - "To evaluate the efficacy of periarticular corticosteroid injection of the sacroiliac joint (SIJ) in patients with seronegative spondylarthropathy in a double blind, controlled study. " 03/01/2006 - "Efficacy of a second magnetic resonance (MR) imaging guided corticosteroid injection of inflamed sacroiliac joints (SIJ) in patients with spondylarthropathy. " 01/01/1994 - "Prognostic significance of synovial fluid analysis in estimating the efficacy of intra-articular corticosteroid injection in patients with spondylarthropathy." 06/01/2016 - "We studied the efficacy and changes in US findings at Achilles enthesitis after corticosteroid injection in patients with spondyloarthropathy (SpA). "
4.	Pamidronate (Aredia)FDA LinkGeneric 12/01/2012 - "Assessment of efficacy of pamidronate in undifferentiated spondyloarthropathy (uSpA): a placebo control trial in a tertiary level center." 05/01/2006 - "Transient efficacy of pulse pamidronate treatment in active spondylarthropathies: an open study of 35 cases." 10/01/2013 - "Assessment of efficacy of pamidronate in undifferentiated spondyloarthropathy (uSpA): a molecular mechanism." 04/01/2005 - "The concept of pamidronate in spondyloarthropathy management should be evaluated further in light of these clinical studies and could have a major impact on our resource-restricted setting." 04/01/2005 - "Pamidronate--a promising new candidate for the management of spondyloarthropathy."
5.	Etanercept (Enbrel)FDA Link 09/01/2001 - "Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study." 03/01/2007 - "Although this was not a double-blind, prospective, randomised study, the strong improvement noticed in the half-dose group suggests that etanercept 25 mg once a week can induce major clinical and biological relief in some patients with RA or spondylarthropathy." 03/01/2004 - "Ten patients classified to have uSpA according to modified European Spondylarthropathy Study Group criteria in a severe and active stage of disease were included in the study and received etanercept in a dosage of 25 mg two times a week for 12 weeks, followed by an observation period of 12 weeks. " 09/01/2011 - "Etanercept in spondyloarthropathies. " 09/01/2011 - "Etanercept (ETN) and other anti-TNF-α agents have revolutionised the management of spondyloarthropathies (SpA). "
6.	Monoclonal AntibodiesIBA 12/01/1996 - "Combination therapy of anti-CD4 and anti-IL6 monoclonal antibodies in a case of severe spondylarthropathy." 06/01/2000 - "In this open-label pilot study of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha in patients with active spondyloarthropathy, there was a fast and significant improvement of axial and peripheral articular manifestations, without major adverse experiences." 03/01/1990 - "In order to study local immunoregulatory mechanisms in patients with seronegative spondylarthropathy and histological evidence of asymptomatic intestinal inflammation, we determined mononuclear cells in distal ileal mucosa with an indirect immunoperoxidase technique using a panel of monoclonal antibodies. " 12/01/2002 - "In the clinic, monoclonal antibodies are proving to be safe and effective for the treatment of a wide range of diseases including rheumatoid arthritis, Crohn's disease, spondyloarthropathies, psoriasis and allograft rejection." 01/01/2008 - "Our aim was to describe three patients with spondyloarthropathies who responded to infliximab, a chimeric monoclonal antibody specific for TNF-α but developed new symptoms of spondyloarthropathies. "
7.	SteroidsIBA 11/01/1997 - "The lack of response to low dose of steroids prompted us to reconsider this diagnosis and, after a careful evaluation and taking into account past clinical history, a final diagnosis of spondyloarthropathy (SpA) was made. " 11/01/2007 - "Steroid treatment is often effective for uveitis associated with spondyloarthropathies. " 10/15/2001 - "Two women with spondylarthropathy involving very painful sacroiliac arthritis for 18 and 24 months had been relieved only transiently by several injections of steroids into the sacroiliac joint under fluoroscopy and by Bermuda casts. " 01/01/1997 - "Steroid joint injections may be effective in painful joints due to degenerative disease and posttraumatic changes, as well as rheumatoid arthritis and seronegative spondylarthropathy. " 01/01/2018 - "The primary objective of this case series was to report the use of cervical epidural steroid injection in the management of neck pain and stiffness secondary to spondyloarthropathy in cases refractory to conservative therapy. "
8.	HLA-B27 Antigen (HLA B27 Antigen)IBA 08/01/1998 - "To assess aerobic fitness (AF) and physical activity (PA) in patients with HLA-B27 positive juvenile spondyloarthropathy (JSpA) in remission at the time of testing. " 08/01/1998 - "Aerobic fitness and physical activity in patients with HLA-B27 positive juvenile spondyloarthropathy that is inactive or in remission." 08/01/1990 - "HLA-B27 has revitalized the epidemiology of spondyloarthropathies and has helped to broaden the clinical spectrum of these diseases. " 08/01/2022 - "A study of clinical, radiological features and HLA-B27 serology of axial spondyloarthropathy with comparison of radiographic and non-radiographic disease." 10/01/2013 - "A total of 368 AS patients with positive HLA-B27 status from the Observation Study of Korean spondyloArthropathy Registry (OSKAR) cohort were recruited for this study. "
9.	Sulfasalazine (Azulfidine)FDA LinkGeneric 07/01/1993 - "These data suggest that sulfasalazine is an effective and safe second-line drug for the management of severe juvenile spondyloarthropathies." 10/01/2002 - "A 26 week randomised, double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies." 11/01/1999 - "Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study." 11/01/1995 - "The persistence of enthesopathic changes was studied by ultrasound (US) in 23 patients with spondylarthropathy during a 6-month prospective trial with sulphasalazine (Salazopyrin). " 07/01/1993 - "The efficacy and safety of sulfasalazine for the treatment of juvenile spondyloarthropathy were evaluated in an open study. "
10.	Adalimumab (Humira)FDA Link 01/01/2019 - "This retrospective review of prospectively followed cohort of spondyloarthropathy patients aimed to evaluate the efficacy of simultaneous initiation of adalimumab with LTBI treatment. " 01/01/2010 - "We describe a 66-year-old man taking adalimumab for spondyloarthropathy who developed an inflammatory infiltration in his right index finger. " 01/01/2014 - "Adalimumab for recurrent inflammatory discitis associated with spondyloarthropathy." 01/01/2016 - "Adalimumab has shown efficacy in treating refractory uveitis in multiple settings, including idiopathic disease, juvenile idiopathic arthritis, sarcoidosis, Behçets disease, and uveitis secondary to spondyloarthropathies, among several other noninfectious uveitis conditions. " 07/14/2023 - "Generalized pustular psoriasis-like widespread eruption following COVID-19 infection in a patient with spondyloarthropathy on adalimumab."

Therapies and Procedures

1.	Therapeutics 10/01/2013 - "Fifty-nine patients with SpA according to the European Spondylarthropathy Study Group criteria who were treated with anti-TNF therapy for at least 4 years were included. " 12/28/2017 - "Role of Stem Cells in Pathophysiology and Therapy of Spondyloarthropathies-New Therapeutic Possibilities?" 04/01/2015 - "This review discusses the current understanding of the interplay between host genetics and the gut microbiome in the pathogenesis of spondyloarthropathies, and how this may relate to potential therapies for these conditions. " 12/01/2014 - "We described a 52-year-old woman, diagnosed as a case of undifferentiated spondyloarthropathy for ten years, who was unresponsive to classic anti-inflammatory therapies. " 08/01/2012 - "This approach is less successful in spondylarthropathies, for which non-steroidal anti-inflammatory drugs remain first-line therapy. "
2.	Injections 05/01/2009 - "This study was designed to evaluate the efficacy and safety of unguided sacroiliac injections for refractory sacroiliac pain due to spondyloarthropathies. " 07/10/2021 - "The search strategies used the search terms 'spondyloarthropathies', 'inflammatory arthritis', 'achilles tendon', 'physical therapy', 'conservative management', 'injections', and related synonyms. " 08/01/2009 - "Intraarticular sacroiliac joint corticosteroid injections are effective in patients with spondyloarthropathy. " 03/01/2000 - "Efficacy of sacroiliac corticosteroid injections in patients with inflammatory spondyloarthropathy: results of a 6 month controlled study." 08/01/1996 - "Assessment of the efficacy of sacroiliac corticosteroid injections in spondylarthropathies: a double-blind study."
3.	Physical Therapy Modalities (Physical Therapy Technique) 01/01/1998 - "Intensive group physiotherapy is beneficial for patients with spondyloarthropathy." 12/01/2000 - "Does improved spinal mobility correlate with functional changes in spondyloarthropathy after short term physical therapy?" 01/01/2004 - "Physical therapy is one of the most important way to restore function and health status in patients with spondyloarthropathies, esspecially individual kinesitherapy. " 01/01/2004 - "[Spondyloarthropathies--clinical evaluation and physical therapy]." 11/01/1998 - "Spondylarthropathy treatment: progress in medical treatment, physical therapy and rehabilitation."
4.	Immunomodulation 09/01/2000 - "Anti-inflammatory and immunomodulatory therapies in spondyloarthropathies." 08/01/2003 - "Infliximab in patients who have spondyloarthropathy: clinical efficacy, safety, and biological immunomodulation." 11/01/2014 - "Immunomodulatory therapy that also acts as a corticosteroid sparing therapy can be effective in controlling chronic uveitis in patients with spondyloarthropathy." 03/01/2014 - "Infliximab and adalimumab can be considered as potential second-line immunomodulatory agents for the treatment of severe ocular inflammatory conditions including posterior uveitis, panuveitis, severe uveitis associated with seronegative spondyloarthropathy, and scleritis in patients requiring immunomodulation in patients who have failed or who are not candidates for antimetabolite or calcineurin inhibitor immunomodulation. "
5.	Aftercare (After-Treatment) 10/01/2003 - "Bone mineral density improvement in spondyloarthropathy after treatment with etanercept." 01/01/2014 - "Synovial enhancement is significantly reduced after treatment, and unlike adults, synovial enhancement may be detected without accompanying bone marrow edema, which suggests gadolinium contrast may be an important component in the assessment of children with spondyloarthropathy."